Author: therawinformant

If you are looking for the best ideas for your portfolio you may want to consider some of Ensemble Capital's top stock picks. Ensemble Capital, an investment management firm, is bullish on Starbucks Corp (NASDAQ:SBUX) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed its investment […]

from Yahoo Finance https://ift.tt/2VFmnyC

Stanphyl Capital letter to investors for the month ended June 30, 2020, discussing their short thesis for Tesla Inc (NASDAQ:TSLA) and other positions in several small-cap stocks. For June 2020 the fund was down 3.9% net of all fees and expenses. By way of comparison, the S&P 500 was up 2.0% while the Russell 2000 was up […]

from Yahoo Finance https://ift.tt/2VLonVW

No pain, no gain goes the well-worn axiom. A stock market themed inverse can read: no gain, shareholder pain. You can currently apply the latter to Intercept Pharmaceuticals (ICPT). The small-cap biotech was hoping to gain the FDA’s nod of approval for its liver disease therapy, but there was only pain to endure, as the NDA was rejected. As a result, shares were sent tumbling by 40% on Monday June 29. So, what happened exactly? ICPT received a CRL from the FDA regarding its obeticholic acid (OCA) treatment in advanced-stage non-alcoholic steatohepatitis (NASH), due to a lack of evidence showing that the benefits of the treatment outweigh the potential risks. The FDA recommended that data from the ongoing Phase 3 REGENERATE study be further analyzed. NASH is a fatty liver disease, closely related to obesity, for which there are currently no specific drugs available. Due to the rising obesity rates, the market for NASH medications is expected to grow considerably over the next few years, with some estimates putting its worth at $35 billion. Intercept’s application was based on data from the treatment of over 1,700 NASH patients across 35 clinical trials. Management expects to schedule a meeting with the FDA in 2H20 to discuss how to move forward. Needham analyst Alan Carr expects the NDA to be resubmitted before the end of the year, and anticipates “the drug will be approved in the U.S. by mid-2021.” The analyst believes the rejection might have more to do with the current macro climate than with the data itself. Carr said, “We acknowledge the FDA clearly has some level of concern w/ OCA, however, we believe COVID-19 has played a role in disrupting and preventing completion of the review process. We await the outcome of the meeting with the FDA and assume resubmission by YE20. We still believe OCA will be approved in NASH, but have reduced our target due to launch delay.” That price target is slashed from $150 to $100, although the figure still implies hefty upside potential of 115%. Carr made no change to the rating, which remains a Buy. (To watch Carr’s track record, click here) Looking at the consensus breakdown, based on 6 Buys and 15 Holds, ICPT has a Moderate Buy consensus rating. With an average price target of $66.10, the analysts forecast possible upside of 42% over the next 12 months. (See Intercept price targets and analyst ratings on TipRanks)

from Yahoo Finance https://ift.tt/3ePcYff

We at Insider Monkey have gone over 821 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of March 31st, near the height of the coronavirus market crash. We are almost done with the second quarter. Investors decided […]

from Yahoo Finance https://ift.tt/3gcCXgK

Every investor in Agenus Inc. (NASDAQ:AGEN) should be aware of the most powerful shareholder groups. Institutions will…

from Yahoo Finance https://ift.tt/2BzP7lm

Yahoo Finance’s Adam Shapiro breaks down Thursday’s top trending headlines.

from Yahoo Finance https://ift.tt/3ioRDLX

Royal Dutch Shell is not ruling out moving its headquarters from the Netherlands to Britain, the oil company’s chief executive Ben van Beurden said in a Dutch newspaper interview published on Saturday. Anglo-Dutch consumer products giant Unilever said last month it plans to ditch its dual Anglo-Dutch legal structure and create a single entity in Britain. Van Beurden did not explicitly say Shell wants to move its headquarters, het Financieele Dagblad said.

from Yahoo Finance https://ift.tt/2YVGzOG

Luke Lloyd, a wealth advisor at Strategic Wealth Partners, joins Yahoo Finance to highlight how some Americans are using the COVID-19 pandemic as an opportunity to reset retirement goals.

from Yahoo Finance https://ift.tt/2VJ4wGJ

Those following along with T-Mobile US, Inc. (NASDAQ:TMUS) will no doubt be intrigued by the recent purchase of shares…

from Yahoo Finance https://ift.tt/3dYny28

from Yahoo Finance https://ift.tt/31FuXRH